Circulating tumor DNA and late recurrence in high-risk hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer.

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer – Journal of Clinical Oncology

Editorial: Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor–Positive Early Breast Cancer?

Commentary: Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in Advance — First evidence for patients in late adjuvant setting, years after initial diagnosis – MedPage Today (free registration required)

Commentary on Twitter

103 women in long-term remission from high-risk HR+/HER2- breast cancer had customized monitoring of recurrence based on ctDNA seq for tumour-associated mut. Among 8 pts MRD+ pts, 6 developed distant recurrence at a median 12.4 mo after ctDNA positivity https://t.co/aX1ruLCSbb

— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022